DAX+0,21 % EUR/USD-0,16 % Gold-0,41 % Öl (Brent)+1,02 %

Es geht schon wieder los



Beitrag schreiben

Begriffe und/oder Benutzer

 

Lange nicht mehr so einen interessanten Wert gesehen. Hab alles verkauft und bin hier all in👍
Zahlen heute erwartet
Antwort auf Beitrag Nr.: 60.110.506 von Fusselsocke am 15.03.19 13:26:11Bin der Meinung wir knacken gleich die 3,50👍
Antwort auf Beitrag Nr.: 60.110.647 von Fusselsocke am 15.03.19 13:43:16
Zitat von Fusselsocke: Bin der Meinung wir knacken gleich die 3,50👍


denke du hast sicher 2,50 gemeint. :look:
Antwort auf Beitrag Nr.: 60.111.304 von bmuesli am 15.03.19 14:48:16Nein, ich meine 3,50!
Die Amis haben doch grad 20 min auf😏
Antwort auf Beitrag Nr.: 60.111.337 von Fusselsocke am 15.03.19 14:50:20
Zitat von Fusselsocke: Nein, ich meine 3,50!
Die Amis haben doch grad 20 min auf😏


wie viele Reversesplits hat es denn da in den letzten Jahren schon gegeben? Das müssen ja schon einige gewesen sein wenn man sich den Chart anschaut.
Antwort auf Beitrag Nr.: 60.111.385 von bmuesli am 15.03.19 14:56:33Ich bleibe dabei: das hier wird Gold wert sein
Antwort auf Beitrag Nr.: 60.112.486 von Fusselsocke am 15.03.19 16:22:03es bleibt dir auch nichts anderes übrig wenn du wirklich all in bist. :D Du solltest dir auch mal Epigenomics anschauen denke da könnte durchaus auch enormes Potential vorhanden sein.
Antwort auf Beitrag Nr.: 60.113.386 von bmuesli am 15.03.19 17:43:01Das stimmt😔 leider ging es eher runter als hoch. ich rechne aber weiterhin mit einem sehr guten Kursverlauf und bleibe „all in“
Antwort auf Beitrag Nr.: 60.148.788 von Fusselsocke am 20.03.19 10:37:06denke aber die Monsanto Nachricht wird erst einmal die Biotechs belasten.
Antwort auf Beitrag Nr.: 60.110.506 von Fusselsocke am 15.03.19 13:26:11
Zitat von Fusselsocke: Lange nicht mehr so einen interessanten Wert gesehen. Hab alles verkauft und bin hier all in👍
Zahlen heute erwartet


https://www.tonixpharma.com/news-events/press-releases/detai…
NEW YORK, March 18, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix, or the Company), a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense, today announced financial results for the fourth quarter and full year ended December 31, 2018, and an overview of recent operational highlights.

“Looking forward into 2019, we are excited about the recent initiation of our new Phase 3 study of Tonmya for PTSD. The RECOVERY study incorporates learnings and analyses from our Phase 2 and Phase 3 studies in over 500 military-related PTSD participants, and is intended to support the registration of Tonmya for PTSD. We look forward to topline data in the first half of 2020,” said Seth Lederman, M.D., President and Chief Executive Officer. “In addition to Tonmya for PTSD, we maintain a strong and growing pipeline of product candidates, including TNX-102 SL as a bedtime treatment for fibromyalgia and agitation in Alzheimer’s disease, and TNX-601 as a daytime treatment for PTSD and neurocognitive dysfunction associated with corticosteroid use, a potential indication.”

Recent Clinical and Regulatory Highlights
•Enrolled first participant in the Phase 3 RECOVERY study of Tonmya for the treatment of PTSD in March. This pivotal efficacy study incorporates several innovative design features, based on analyses of data from our prior PTSD trials. In November 2018, we received Food and Drug Administration (FDA) acceptance of the study design, which includes participants who have experienced civilian traumas in addition to those with military-related traumas, and restricts enrollment to participants who experienced an index trauma within nine years of screening.


•Completed a Clinical Guidance meeting with the FDA in March to discuss the fibromyalgia registration plan for TNX-102 SL and a new Phase 3 study to support this indication.


•Received European use patent issuance for TNX-601 (tianeptine oxalate) for the treatment of neurocognitive dysfunction associated with corticosteroids use, a potential indication. TNX-601 is also being developed as a daytime treatment for PTSD. A Phase 1 pharmacokinetic study of proprietary tianeptine oxalate formulations will be conducted outside of the U.S. and the result is expected in the second half of 2019.

•Successfully completed a Phase 1 pivotal bridging pharmacokinetic study of TNX-102 SL in 2018, the data for which was deemed sufficient by the FDA to support the 505(b)(2) NDA submission for Tonmya and TNX-102 SL.

Recent Corporate Highlights
•Strengthened our balance sheet in December 2018 by completing a public equity offering. The transaction resulted in gross proceeds of $15.9 million, including the over-allotment proceeds, which will be used, in part, to fund the new Phase 3 RECOVERY trial of Tonmya for PTSD.


•Announced a Share Repurchase Program to buy up to $2 million in value of the Company’s outstanding stock from time to time.

Fourth Quarter 2018 Financial Results

Research and development expenses for the fourth quarter of 2018 totaled $5.1 million, compared to $3.6 million for the same period in 2017. This increase is due primarily to costs related to the close-out of the Phase 3 HONOR study as well as other activities related to the PTSD program.

General and administrative expenses for the fourth quarter of 2018 were $2.6 million, compared to $1.9 million for the same period in 2017. This increase is due primarily to an increase in legal fees related to patent prosecution, as well as an increase in investor and public relations expenses due to increased investor meetings.

Net loss available to common stockholders was $10.9 million, or $6.10 per share, for the fourth quarter of 2018, compared to net loss of $5.5 million, or $7.07 per share, for the fourth quarter of 2017. In addition to the factors above, fourth quarter 2018 net loss available to common stockholders was impacted by a one-time, non-cash preferred stock deemed dividend in the fourth quarter of 2018. The weighted average common shares outstanding, basic and diluted for the fourth quarter of 2018 was 1,778,524 shares. The weighted average common shares outstanding, basic and diluted for the fourth quarter of 2017 was 750,804 shares.

As of March 13, 2019, all Series A convertible preferred stock had been converted into common stock. Total common stock outstanding as of March 13, 2019 was 6,089,728.

Full Year 2018 Financial Results

Research and development expenses for full year 2018 totaled $17.6 million, compared to $13.3 million for full year 2017. This increase is due primarily to the continued development work related to the PTSD program, including the completion of the NDA-required pivotal bridging pharmacokinetic study of TNX-102 SL in 2018.

General and administrative expenses for full year 2018 were $8.8 million, compared to $8.0 mill


Beitrag zu dieser Diskussion schreiben